Anticoagulation for Stroke Prevention

Anticoagulation is essential for preventing cardioembolic stroke and recurrent thrombosis in specific high-risk conditions. Unlike antiplatelet therapy (which targets arterial atherothrombosis), anticoagulants are indicated when the stroke mechanism involves cardiac embolism, venous thrombosis, or hypercoagulable states. Selecting the right anticoagulant—and knowing when not to use DOACs—is critical.

Indications for Anticoagulation in Stroke Prevention

Atrial Fibrillation

Atrial fibrillation (AF) is the most common indication for anticoagulation in stroke prevention. Left atrial stasis leads to thrombus formation (typically in the left atrial appendage), which can embolize to the brain. The annual stroke risk in AF ranges from 1–15% depending on CHA₂DS₂-VASc score.

DOACs vs Warfarin: The Landmark Trials

Four pivotal trials established DOACs as the preferred agents for stroke prevention in non-valvular AF:

RE-LY (2009) — Dabigatran 150mg BID reduced stroke/SE by 34% vs warfarin with similar major bleeding; 110mg BID was non-inferior with less bleeding.

ROCKET-AF (2011) — Rivaroxaban 20mg daily was non-inferior to warfarin for stroke/SE, with similar major bleeding but less intracranial hemorrhage.

ARISTOTLE (2011) — Apixaban 5mg BID reduced stroke/SE by 21%, major bleeding by 31%, and mortality by 11% vs warfarin—the only DOAC to show mortality benefit.

ENGAGE AF-TIMI 48 (2013) — Edoxaban 60mg daily was non-inferior to warfarin with significantly less bleeding and cardiovascular death.

Timing of Anticoagulation After AF-Related Stroke

The traditional concern about early anticoagulation was hemorrhagic transformation of the infarct. Four randomized trials and a pooled meta-analysis have now established the safety of early DOAC initiation.

TIMING (2022) — 888 patients randomized to early (≤4 days) vs delayed (5–10 days) DOAC. Primary composite at 90 days: 2.9% early vs 4.1% delayed. Symptomatic ICH 0.2% vs 0.4%. Demonstrated non-inferiority of early initiation.

ELAN (2023) — 2,013 patients randomized to early vs late DOAC based on infarct size (early = ≤48h for minor/moderate, days 6–7 for major). Primary composite at 30 days: 2.9% early vs 4.1% late. Symptomatic ICH 0.2% in both groups. Trend favoring early initiation, with lower recurrent ischemic stroke (1.4% vs 2.5%).

OPTIMAS (2024) — 3,621 patients randomized to early (≤4 days) vs delayed (7–14 days) DOAC. Primary outcome at 90 days: 3.3% in both groups. Symptomatic ICH 0.6% vs 0.7%. Confirms safety of early anticoagulation across all stroke severities.

START (2025) — 200 patients randomized to DOAC initiation at day 3–4, day 6, day 10, or day 14. Day 3–4 group had no ischemic events and highest probability of being optimal. Supports earlier initiation within the first week.

CATALYST Meta-Analysis (2025) — Pooled individual patient data from TIMING, ELAN, OPTIMAS, and START (>6,500 patients). Early DOAC initiation (≤4 days) reduced the composite of recurrent ischemic stroke, symptomatic ICH, or unclassified stroke at 30 days compared to delayed initiation.

Mechanical Heart Valves

Patients with mechanical prosthetic heart valves require lifelong anticoagulation. Warfarin is the ONLY option—DOACs are contraindicated and cause harm.

RE-ALIGN Trial (2013)

This trial tested dabigatran vs warfarin in patients with mechanical heart valves:

• Stopped early for harm
• Dabigatran: More thromboembolic events (5% vs 0%) and major bleeding (4% vs 2%)
• Mechanism: Mechanical valves require consistent suppression of contact pathway activation—dabigatran's pharmacokinetics inadequate

Antiphospholipid Syndrome (APS)

Antiphospholipid syndrome causes arterial and venous thrombosis through antibody-mediated endothelial dysfunction and platelet activation. High-risk ("triple-positive") patients have lupus anticoagulant, anti-cardiolipin, and anti-β2-glycoprotein I antibodies.

TRAPS Trial (2018) + 2-Year Follow-up (2021)

Rivaroxaban vs warfarin in triple-positive APS:

• Stopped early for excess arterial thrombosis in rivaroxaban arm
• 2-year outcomes: Composite events 33.3% (rivaroxaban) vs 5.7% (warfarin), HR 6.9
• Thrombotic events: HR 13.3 favoring warfarin

ASTRO-APS/TAPS Trial (2022)

Apixaban vs warfarin in thrombotic APS:

• Stopped early—all strokes occurred in apixaban group (6/23 vs 0/25)
• Demonstrates class effect: DOACs inadequate for APS

Cervical Artery Dissection

Cervical artery dissection (carotid or vertebral) causes stroke through artery-to-artery embolism from the intimal flap or vessel occlusion. The optimal antithrombotic strategy has been debated for decades.

CADISS Trial (2015)

250 patients randomized to antiplatelet vs anticoagulation within 7 days of dissection:

• Stroke at 3 months: 2.5% in both groups (no difference)
• Recurrent stroke was rare overall (low event rate limited power)
• Recanalization rates similar between groups

TREAT-CAD (2021)

Aspirin vs vitamin K antagonist in cervical artery dissection:

• Aspirin did not meet non-inferiority criteria
• Trend toward more strokes with aspirin (3.3% vs 1.5%)
• Subgroup analysis: Anticoagulation may benefit occlusive dissection (HR 0.40)

Practical Approach

• Either antiplatelet or anticoagulation is acceptable (CADISS)
• Consider anticoagulation for: occlusive dissection, recurrent events, extensive thrombus
• Duration: Typically 3–6 months, then reassess with imaging
• DOACs increasingly used (no RCT data, but observational studies suggest safety)

Cerebral Venous Thrombosis (CVT)

CVT requires anticoagulation to prevent thrombus propagation and facilitate recanalization. Historically, heparin followed by warfarin was standard. DOACs are now emerging as alternatives.

RE-SPECT CVT (2019)

Dabigatran 150mg BID vs warfarin for 24 weeks after initial parenteral anticoagulation:

• Recurrent VTE: 0% in both arms
• Major bleeding: 1.7% (dabigatran) vs 3.3% (warfarin)
• Recanalization: 60% vs 67% (similar)
• Functional outcome (mRS 0–1): 91.5% vs 91.4%

ACTION-CVT / DOAC-CVT Registries

Large observational studies confirm DOACs appear safe and effective in CVT, with similar or lower bleeding rates than warfarin.

Practical Approach

• DOACs are reasonable alternatives to warfarin for CVT
• Start with parenteral anticoagulation (heparin/LMWH) in acute phase
• Transition to oral anticoagulation once stable
• Duration: 3–12 months depending on provoked vs unprovoked and risk factors

LV Thrombus and Intracardiac Thrombus

Left ventricular thrombus typically forms after anterior MI with akinetic/dyskinetic segments, or in dilated cardiomyopathy. Anticoagulation prevents systemic embolization.

Current Evidence

• Warfarin is traditional standard (INR 2–3 for 3–6 months)
• DOACs: Observational data suggest similar efficacy; RCTs ongoing
• Some studies suggest higher thrombus persistence with DOACs vs warfarin
• Consider warfarin for large/mobile thrombi; DOACs may be acceptable for smaller thrombi

Detection

Cardiac CT angiography (CCTA) detects LV/LA thrombus in up to 17% of cryptogenic stroke patients—significantly more than TTE alone. Consider extended cardiac imaging in ESUS workup.

Patent Foramen Ovale (PFO)

PFO allows paradoxical embolism from venous thrombi. In cryptogenic stroke with high-risk PFO features (large shunt, atrial septal aneurysm), closure is preferred over medical therapy.

Key Trials

CLOSE (2017) — PFO closure reduced stroke from 14 events to 0 vs antiplatelets alone (HR 0.03) in patients with ASA or large shunt.

RESPECT (Extended, 2017) — PFO closure reduced recurrent stroke (HR 0.55 overall; HR 0.38 for cryptogenic stroke).

REDUCE (2017) — Closure reduced stroke from 5.4% to 1.4% (HR 0.23).

Hierarchy of Evidence

1. PFO closure + antiplatelet — Most effective for high-risk features
2. Anticoagulation — Reasonable if closure not feasible (CLOSE showed trend toward benefit)
3. Antiplatelet alone — Least effective in high-risk PFO

Other Indications

Rheumatic Mitral Stenosis

Patients with rheumatic mitral valve disease and AF require warfarin. They were excluded from DOAC trials, so no data support DOAC use.

Cancer-Associated Stroke

Trousseau syndrome (cancer hypercoagulability) may cause stroke. LMWH or DOACs (edoxaban, rivaroxaban) are options depending on cancer type and bleeding risk.

Inherited Thrombophilias

Factor V Leiden, prothrombin mutation, protein C/S deficiency—anticoagulation indicated for venous events. Arterial stroke from thrombophilia is less common; treatment individualized.

Oral Anticoagulant Pharmacology Comparison